APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hip Osteoarthritis Pain Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Hip Osteoarthritis Pain Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025193 pages

Choose your research edition.

Industry ResearchHip Osteoarthritis Pain Drug Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal Hip Osteoarthritis Pain Drug Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Hip Osteoarthritis Pain Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hip Osteoarthritis Pain Drug Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Hip Osteoarthritis Pain Drug Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Hip Osteoarthritis Pain Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Hip Osteoarthritis Pain Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hip Osteoarthritis Pain Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hip Osteoarthritis Pain Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Hip Osteoarthritis Pain Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Hip Osteoarthritis Pain Drug include Abiogen Pharma, Almatica Pharma, Astellas Pharma, Horizon Pharma, Iroko Pharmaceuticals, Tide Pharmaceutical, Bayer, Daiichi Sankyo and GlaxoSmithKline, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hip Osteoarthritis Pain Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hip Osteoarthritis Pain Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hip Osteoarthritis Pain Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hip Osteoarthritis Pain Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Hip Osteoarthritis Pain Drug Segment by Company

Abiogen Pharma

Almatica Pharma

Astellas Pharma

Horizon Pharma

Iroko Pharmaceuticals

Tide Pharmaceutical

Bayer

Daiichi Sankyo

GlaxoSmithKline

Pfizer

Hengrui Pharmaceutical

Eli Lilly

Mylan

Novartis

Johnson and Johnson

Sanofi

TEVA

Abbott

Hip Osteoarthritis Pain Drug Segment by Type

Injection

External

Oral

Hip Osteoarthritis Pain Drug Segment by Application

Medical Care

Personal Care

Hip Osteoarthritis Pain Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hip Osteoarthritis Pain Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hip Osteoarthritis Pain Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hip Osteoarthritis Pain Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hip Osteoarthritis Pain Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Hip Osteoarthritis Pain Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Hip Osteoarthritis Pain Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Hip Osteoarthritis Pain Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Hip Osteoarthritis Pain Drug Industry Trends Table 2. Hip Osteoarthritis Pain Drug Industry Drivers Table 3. Hip Osteoarthritis Pain Drug Industry Opportunities and Challenges Table 4. Hip Osteoarthritis Pain Drug Industry Restraints Table 5. Global Hip Osteoarthritis Pain Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Hip Osteoarthritis Pain Drug Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Hip Osteoarthritis Pain Drug Sales Market Share by Manufacturers Table 9. Global Hip Osteoarthritis Pain Drug Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Hip Osteoarthritis Pain Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Hip Osteoarthritis Pain Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Hip Osteoarthritis Pain Drug Manufacturers, Product Type & Application Table 13. Global Hip Osteoarthritis Pain Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Hip Osteoarthritis Pain Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Injection Table 17. Major Manufacturers of External Table 18. Major Manufacturers of Oral Table 19. Global Hip Osteoarthritis Pain Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Hip Osteoarthritis Pain Drug Sales by Type (2021-2026) & (k units) Table 21. Global Hip Osteoarthritis Pain Drug Sales by Type (2027-2032) & (k units) Table 22. Global Hip Osteoarthritis Pain Drug Sales Market Share by Type (2021-2026) Table 23. Global Hip Osteoarthritis Pain Drug Sales Market Share by Type (2027-2032) Table 24. Global Hip Osteoarthritis Pain Drug Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Hip Osteoarthritis Pain Drug Revenue by Type (2021-2026) & (k units) Table 26. Global Hip Osteoarthritis Pain Drug Revenue by Type (2027-2032) & (k units) Table 27. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Type (2021-2026) Table 28. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Medical Care Table 30. Major Manufacturers of Personal Care Table 31. Global Hip Osteoarthritis Pain Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Hip Osteoarthritis Pain Drug Sales by Application (2021-2026) & (k units) Table 33. Global Hip Osteoarthritis Pain Drug Sales by Application (2027-2032) & (k units) Table 34. Global Hip Osteoarthritis Pain Drug Sales Market Share by Application (2021-2026) Table 35. Global Hip Osteoarthritis Pain Drug Sales Market Share by Application (2027-2032) Table 36. Global Hip Osteoarthritis Pain Drug Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Hip Osteoarthritis Pain Drug Revenue by Application (2021-2026) & (k units) Table 38. Global Hip Osteoarthritis Pain Drug Revenue by Application (2027-2032) & (k units) Table 39. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Application (2021-2026) Table 40. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Application (2027-2032) Table 41. Global Hip Osteoarthritis Pain Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Hip Osteoarthritis Pain Drug Sales by Region (2021-2026) & (k units) Table 43. Global Hip Osteoarthritis Pain Drug Sales Market Share by Region (2021-2026) Table 44. Global Hip Osteoarthritis Pain Drug Sales Forecasted by Region (2027-2032) & (k units) Table 45. Global Hip Osteoarthritis Pain Drug Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Hip Osteoarthritis Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 47. North America Hip Osteoarthritis Pain Drug Sales by Country (2021-2026) & (k units) Table 48. North America Hip Osteoarthritis Pain Drug Sales by Country (2027-2032) & (k units) Table 49. Europe Hip Osteoarthritis Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. Europe Hip Osteoarthritis Pain Drug Sales by Country (2021-2026) & (k units) Table 51. Europe Hip Osteoarthritis Pain Drug Sales by Country (2027-2032) & (k units) Table 52. Asia Pacific Hip Osteoarthritis Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Asia Pacific Hip Osteoarthritis Pain Drug Sales by Country (2021-2026) & (k units) Table 54. Asia Pacific Hip Osteoarthritis Pain Drug Sales by Country (2027-2032) & (k units) Table 55. South America, Middle East and Africa Hip Osteoarthritis Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. South America, Middle East and Africa Hip Osteoarthritis Pain Drug Sales by Country (2021-2026) & (k units) Table 57. South America, Middle East and Africa Hip Osteoarthritis Pain Drug Sales by Country (2027-2032) & (k units) Table 58. Global Hip Osteoarthritis Pain Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Hip Osteoarthritis Pain Drug Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Hip Osteoarthritis Pain Drug Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Region (2021-2026) Table 62. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Region (2027-2032) Table 63. Abiogen Pharma Company Information Table 64. Abiogen Pharma Business Overview Table 65. Abiogen Pharma Hip Osteoarthritis Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Abiogen Pharma Hip Osteoarthritis Pain Drug Product Portfolio Table 67. Abiogen Pharma Recent Development Table 68. Almatica Pharma Company Information Table 69. Almatica Pharma Business Overview Table 70. Almatica Pharma Hip Osteoarthritis Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Almatica Pharma Hip Osteoarthritis Pain Drug Product Portfolio Table 72. Almatica Pharma Recent Development Table 73. Astellas Pharma Company Information Table 74. Astellas Pharma Business Overview Table 75. Astellas Pharma Hip Osteoarthritis Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Astellas Pharma Hip Osteoarthritis Pain Drug Product Portfolio Table 77. Astellas Pharma Recent Development Table 78. Horizon Pharma Company Information Table 79. Horizon Pharma Business Overview Table 80. Horizon Pharma Hip Osteoarthritis Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Horizon Pharma Hip Osteoarthritis Pain Drug Product Portfolio Table 82. Horizon Pharma Recent Development Table 83. Iroko Pharmaceuticals Company Information Table 84. Iroko Pharmaceuticals Business Overview Table 85. Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Product Portfolio Table 87. Iroko Pharmaceuticals Recent Development Table 88. Tide Pharmaceutical Company Information Table 89. Tide Pharmaceutical Business Overview Table 90. Tide Pharmaceutical Hip Osteoarthritis Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Tide Pharmaceutical Hip Osteoarthritis Pain Drug Product Portfolio Table 92. Tide Pharmaceutical Recent Development Table 93. Bayer Company Information Table 94. Bayer Business Overview Table 95. Bayer Hip Osteoarthritis Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Bayer Hip Osteoarthritis Pain Drug Product Portfolio Table 97. Bayer Recent Development Table 98. Daiichi Sankyo Company Information Table 99. Daiichi Sankyo Business Overview Table 100. Daiichi Sankyo Hip Osteoarthritis Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Daiichi Sankyo Hip Osteoarthritis Pain Drug Product Portfolio Table 102. Daiichi Sankyo Recent Development Table 103. GlaxoSmithKline Company Information Table 104. GlaxoSmithKline Business Overview Table 105. GlaxoSmithKline Hip Osteoarthritis Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. GlaxoSmithKline Hip Osteoarthritis Pain Drug Product Portfolio Table 107. GlaxoSmithKline Recent Development Table 108. Pfizer Company Information Table 109. Pfizer Business Overview Table 110. Pfizer Hip Osteoarthritis Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Pfizer Hip Osteoarthritis Pain Drug Product Portfolio Table 112. Pfizer Recent Development Table 113. Hengrui Pharmaceutical Company Information Table 114. Hengrui Pharmaceutical Business Overview Table 115. Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Product Portfolio Table 117. Hengrui Pharmaceutical Recent Development Table 118. Eli Lilly Company Information Table 119. Eli Lilly Business Overview Table 120. Eli Lilly Hip Osteoarthritis Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Eli Lilly Hip Osteoarthritis Pain Drug Product Portfolio Table 122. Eli Lilly Recent Development Table 123. Mylan Company Information Table 124. Mylan Business Overview Table 125. Mylan Hip Osteoarthritis Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Mylan Hip Osteoarthritis Pain Drug Product Portfolio Table 127. Mylan Recent Development Table 128. Novartis Company Information Table 129. Novartis Business Overview Table 130. Novartis Hip Osteoarthritis Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Novartis Hip Osteoarthritis Pain Drug Product Portfolio Table 132. Novartis Recent Development Table 133. Johnson and Johnson Company Information Table 134. Johnson and Johnson Business Overview Table 135. Johnson and Johnson Hip Osteoarthritis Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Johnson and Johnson Hip Osteoarthritis Pain Drug Product Portfolio Table 137. Johnson and Johnson Recent Development Table 138. Sanofi Company Information Table 139. Sanofi Business Overview Table 140. Sanofi Hip Osteoarthritis Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Sanofi Hip Osteoarthritis Pain Drug Product Portfolio Table 142. Sanofi Recent Development Table 143. TEVA Company Information Table 144. TEVA Business Overview Table 145. TEVA Hip Osteoarthritis Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. TEVA Hip Osteoarthritis Pain Drug Product Portfolio Table 147. TEVA Recent Development Table 148. Abbott Company Information Table 149. Abbott Business Overview Table 150. Abbott Hip Osteoarthritis Pain Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Abbott Hip Osteoarthritis Pain Drug Product Portfolio Table 152. Abbott Recent Development Table 153. Key Raw Materials Table 154. Raw Materials Key Suppliers Table 155. Hip Osteoarthritis Pain Drug Distributors List Table 156. Hip Osteoarthritis Pain Drug Customers List Table 157. Research Programs/Design for This Report Table 158. Authors List of This Report Table 159. Secondary Sources Table 160. Primary Sources List of Figures Figure 1. Hip Osteoarthritis Pain Drug Product Image Figure 2. Global Hip Osteoarthritis Pain Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hip Osteoarthritis Pain Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Hip Osteoarthritis Pain Drug Sales (2021-2032) & (k units) Figure 5. Global Hip Osteoarthritis Pain Drug Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Hip Osteoarthritis Pain Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Injection Image Figure 9. External Image Figure 10. Oral Image Figure 11. Global Hip Osteoarthritis Pain Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Hip Osteoarthritis Pain Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Hip Osteoarthritis Pain Drug Sales Market Share by Type (2021-2032) Figure 14. Global Hip Osteoarthritis Pain Drug Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Hip Osteoarthritis Pain Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Type (2021-2032) Figure 17. Medical Care Image Figure 18. Personal Care Image Figure 19. Global Hip Osteoarthritis Pain Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Hip Osteoarthritis Pain Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Hip Osteoarthritis Pain Drug Sales Market Share by Application (2021-2032) Figure 22. Global Hip Osteoarthritis Pain Drug Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Hip Osteoarthritis Pain Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Application (2021-2032) Figure 25. North America Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 26. North America Hip Osteoarthritis Pain Drug Sales Market Share by Country (2021-2032) Figure 27. U.S. Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 28. Canada Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 29. Mexico Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Hip Osteoarthritis Pain Drug Sales Market Share by Country (2021-2032) Figure 32. Germany Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 33. France Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 34. U.K. Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 35. Italy Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 36. Netherlands Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Hip Osteoarthritis Pain Drug Sales Market Share by Country (2021-2032) Figure 39. China Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 40. Japan Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 41. South Korea Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 42. Southeast Asia Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 43. India Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 44. Australia Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Hip Osteoarthritis Pain Drug Sales Market Share by Country (2021-2032) Figure 47. Brazil Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 48. South Africa Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 49. Saudi Arabia Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 50. Turkey Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 51. Argentina Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 52. UAE Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 53. Egypt Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 54. Chile Hip Osteoarthritis Pain Drug Sales and Growth Rate (2021-2032) & (k units) Figure 55. Global Hip Osteoarthritis Pain Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Hip Osteoarthritis Pain Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Figure 58. North America Hip Osteoarthritis Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Figure 60. Europe Hip Osteoarthritis Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Hip Osteoarthritis Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Hip Osteoarthritis Pain Drug Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Hip Osteoarthritis Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Hip Osteoarthritis Pain Drug Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Hip Osteoarthritis Pain Drug Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • External
  • Oral
Applications
  • Medical Care
  • Personal Care
Companies covered
  • Abiogen Pharma
  • Almatica Pharma
  • Astellas Pharma
  • Horizon Pharma
  • Iroko Pharmaceuticals
  • Tide Pharmaceutical
  • Bayer
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Pfizer
  • Hengrui Pharmaceutical
  • Eli Lilly
  • Mylan
  • Novartis
  • Johnson and Johnson
  • Sanofi
  • TEVA
  • Abbott

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Hip Osteoarthritis Pain Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Hip Osteoarthritis Pain Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Hip Osteoarthritis Pain Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Hip Osteoarthritis Pain Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Hip Osteoarthritis Pain Drug Market Dynamics
  1. 2.1 Hip Osteoarthritis Pain Drug Industry Trends
  2. 2.2 Hip Osteoarthritis Pain Drug Industry Drivers
  3. 2.3 Hip Osteoarthritis Pain Drug Industry Opportunities and Challenges
  4. 2.4 Hip Osteoarthritis Pain Drug Industry Restraints
3 Hip Osteoarthritis Pain Drug Market by Manufacturers
  1. 3.1 Global Hip Osteoarthritis Pain Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Hip Osteoarthritis Pain Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Hip Osteoarthritis Pain Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Hip Osteoarthritis Pain Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Hip Osteoarthritis Pain Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Hip Osteoarthritis Pain Drug Manufacturers, Product Type & Application
  7. 3.7 Global Hip Osteoarthritis Pain Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Hip Osteoarthritis Pain Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Hip Osteoarthritis Pain Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Hip Osteoarthritis Pain Drug Tier 1, Tier 2, and Tier 3
4 Hip Osteoarthritis Pain Drug Market by Type
  1. 4.1 Hip Osteoarthritis Pain Drug Type Introduction
  2. 4.1.1 Injection
  3. 4.1.2 External
  4. 4.1.3 Oral
  5. 4.2 Global Hip Osteoarthritis Pain Drug Sales by Type
  6. 4.2.1 Global Hip Osteoarthritis Pain Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Hip Osteoarthritis Pain Drug Sales by Type (2021-2032)
  8. 4.2.3 Global Hip Osteoarthritis Pain Drug Sales Market Share by Type (2021-2032)
  9. 4.3 Global Hip Osteoarthritis Pain Drug Revenue by Type
  10. 4.3.1 Global Hip Osteoarthritis Pain Drug Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Hip Osteoarthritis Pain Drug Revenue by Type (2021-2032)
  12. 4.3.3 Global Hip Osteoarthritis Pain Drug Revenue Market Share by Type (2021-2032)
5 Hip Osteoarthritis Pain Drug Market by Application
  1. 5.1 Hip Osteoarthritis Pain Drug Application Introduction
  2. 5.1.1 Medical Care
  3. 5.1.2 Personal Care
  4. 5.2 Global Hip Osteoarthritis Pain Drug Sales by Application
  5. 5.2.1 Global Hip Osteoarthritis Pain Drug Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Hip Osteoarthritis Pain Drug Sales by Application (2021-2032)
  7. 5.2.3 Global Hip Osteoarthritis Pain Drug Sales Market Share by Application (2021-2032)
  8. 5.3 Global Hip Osteoarthritis Pain Drug Revenue by Application
  9. 5.3.1 Global Hip Osteoarthritis Pain Drug Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Hip Osteoarthritis Pain Drug Revenue by Application (2021-2032)
  11. 5.3.3 Global Hip Osteoarthritis Pain Drug Revenue Market Share by Application (2021-2032)
6 Global Hip Osteoarthritis Pain Drug Sales by Region
  1. 6.1 Global Hip Osteoarthritis Pain Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hip Osteoarthritis Pain Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Hip Osteoarthritis Pain Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Hip Osteoarthritis Pain Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Hip Osteoarthritis Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Hip Osteoarthritis Pain Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Hip Osteoarthritis Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Hip Osteoarthritis Pain Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Hip Osteoarthritis Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Hip Osteoarthritis Pain Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Hip Osteoarthritis Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Hip Osteoarthritis Pain Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Hip Osteoarthritis Pain Drug Revenue by Region
  1. 7.1 Global Hip Osteoarthritis Pain Drug Revenue by Region
  2. 7.1.1 Global Hip Osteoarthritis Pain Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Hip Osteoarthritis Pain Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Hip Osteoarthritis Pain Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Hip Osteoarthritis Pain Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Hip Osteoarthritis Pain Drug Revenue (2021-2032)
  8. 7.2.2 North America Hip Osteoarthritis Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Hip Osteoarthritis Pain Drug Revenue (2021-2032)
  11. 7.3.2 Europe Hip Osteoarthritis Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Hip Osteoarthritis Pain Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Hip Osteoarthritis Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Hip Osteoarthritis Pain Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Hip Osteoarthritis Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Abiogen Pharma
  2. 8.1.1 Abiogen Pharma Company Information
  3. 8.1.2 Abiogen Pharma Business Overview
  4. 8.1.3 Abiogen Pharma Hip Osteoarthritis Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abiogen Pharma Hip Osteoarthritis Pain Drug Product Portfolio
  6. 8.1.5 Abiogen Pharma Recent Developments
  7. 8.2 Almatica Pharma
  8. 8.2.1 Almatica Pharma Company Information
  9. 8.2.2 Almatica Pharma Business Overview
  10. 8.2.3 Almatica Pharma Hip Osteoarthritis Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Almatica Pharma Hip Osteoarthritis Pain Drug Product Portfolio
  12. 8.2.5 Almatica Pharma Recent Developments
  13. 8.3 Astellas Pharma
  14. 8.3.1 Astellas Pharma Company Information
  15. 8.3.2 Astellas Pharma Business Overview
  16. 8.3.3 Astellas Pharma Hip Osteoarthritis Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Astellas Pharma Hip Osteoarthritis Pain Drug Product Portfolio
  18. 8.3.5 Astellas Pharma Recent Developments
  19. 8.4 Horizon Pharma
  20. 8.4.1 Horizon Pharma Company Information
  21. 8.4.2 Horizon Pharma Business Overview
  22. 8.4.3 Horizon Pharma Hip Osteoarthritis Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Horizon Pharma Hip Osteoarthritis Pain Drug Product Portfolio
  24. 8.4.5 Horizon Pharma Recent Developments
  25. 8.5 Iroko Pharmaceuticals
  26. 8.5.1 Iroko Pharmaceuticals Company Information
  27. 8.5.2 Iroko Pharmaceuticals Business Overview
  28. 8.5.3 Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Product Portfolio
  30. 8.5.5 Iroko Pharmaceuticals Recent Developments
  31. 8.6 Tide Pharmaceutical
  32. 8.6.1 Tide Pharmaceutical Company Information
  33. 8.6.2 Tide Pharmaceutical Business Overview
  34. 8.6.3 Tide Pharmaceutical Hip Osteoarthritis Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Tide Pharmaceutical Hip Osteoarthritis Pain Drug Product Portfolio
  36. 8.6.5 Tide Pharmaceutical Recent Developments
  37. 8.7 Bayer
  38. 8.7.1 Bayer Company Information
  39. 8.7.2 Bayer Business Overview
  40. 8.7.3 Bayer Hip Osteoarthritis Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bayer Hip Osteoarthritis Pain Drug Product Portfolio
  42. 8.7.5 Bayer Recent Developments
  43. 8.8 Daiichi Sankyo
  44. 8.8.1 Daiichi Sankyo Company Information
  45. 8.8.2 Daiichi Sankyo Business Overview
  46. 8.8.3 Daiichi Sankyo Hip Osteoarthritis Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Daiichi Sankyo Hip Osteoarthritis Pain Drug Product Portfolio
  48. 8.8.5 Daiichi Sankyo Recent Developments
  49. 8.9 GlaxoSmithKline
  50. 8.9.1 GlaxoSmithKline Company Information
  51. 8.9.2 GlaxoSmithKline Business Overview
  52. 8.9.3 GlaxoSmithKline Hip Osteoarthritis Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GlaxoSmithKline Hip Osteoarthritis Pain Drug Product Portfolio
  54. 8.9.5 GlaxoSmithKline Recent Developments
  55. 8.10 Pfizer
  56. 8.10.1 Pfizer Company Information
  57. 8.10.2 Pfizer Business Overview
  58. 8.10.3 Pfizer Hip Osteoarthritis Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer Hip Osteoarthritis Pain Drug Product Portfolio
  60. 8.10.5 Pfizer Recent Developments
  61. 8.11 Hengrui Pharmaceutical
  62. 8.11.1 Hengrui Pharmaceutical Company Information
  63. 8.11.2 Hengrui Pharmaceutical Business Overview
  64. 8.11.3 Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Product Portfolio
  66. 8.11.5 Hengrui Pharmaceutical Recent Developments
  67. 8.12 Eli Lilly
  68. 8.12.1 Eli Lilly Company Information
  69. 8.12.2 Eli Lilly Business Overview
  70. 8.12.3 Eli Lilly Hip Osteoarthritis Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Eli Lilly Hip Osteoarthritis Pain Drug Product Portfolio
  72. 8.12.5 Eli Lilly Recent Developments
  73. 8.13 Mylan
  74. 8.13.1 Mylan Company Information
  75. 8.13.2 Mylan Business Overview
  76. 8.13.3 Mylan Hip Osteoarthritis Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Mylan Hip Osteoarthritis Pain Drug Product Portfolio
  78. 8.13.5 Mylan Recent Developments
  79. 8.14 Novartis
  80. 8.14.1 Novartis Company Information
  81. 8.14.2 Novartis Business Overview
  82. 8.14.3 Novartis Hip Osteoarthritis Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Novartis Hip Osteoarthritis Pain Drug Product Portfolio
  84. 8.14.5 Novartis Recent Developments
  85. 8.15 Johnson and Johnson
  86. 8.15.1 Johnson and Johnson Company Information
  87. 8.15.2 Johnson and Johnson Business Overview
  88. 8.15.3 Johnson and Johnson Hip Osteoarthritis Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Johnson and Johnson Hip Osteoarthritis Pain Drug Product Portfolio
  90. 8.15.5 Johnson and Johnson Recent Developments
  91. 8.16 Sanofi
  92. 8.16.1 Sanofi Company Information
  93. 8.16.2 Sanofi Business Overview
  94. 8.16.3 Sanofi Hip Osteoarthritis Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Sanofi Hip Osteoarthritis Pain Drug Product Portfolio
  96. 8.16.5 Sanofi Recent Developments
  97. 8.17 TEVA
  98. 8.17.1 TEVA Company Information
  99. 8.17.2 TEVA Business Overview
  100. 8.17.3 TEVA Hip Osteoarthritis Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 TEVA Hip Osteoarthritis Pain Drug Product Portfolio
  102. 8.17.5 TEVA Recent Developments
  103. 8.18 Abbott
  104. 8.18.1 Abbott Company Information
  105. 8.18.2 Abbott Business Overview
  106. 8.18.3 Abbott Hip Osteoarthritis Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Abbott Hip Osteoarthritis Pain Drug Product Portfolio
  108. 8.18.5 Abbott Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hip Osteoarthritis Pain Drug Value Chain Analysis
  2. 9.1.1 Hip Osteoarthritis Pain Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hip Osteoarthritis Pain Drug Production Mode & Process
  6. 9.2 Hip Osteoarthritis Pain Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hip Osteoarthritis Pain Drug Distributors
  9. 9.2.3 Hip Osteoarthritis Pain Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst